<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841230</url>
  </required_header>
  <id_info>
    <org_study_id>8/46/260</org_study_id>
    <nct_id>NCT00841230</nct_id>
  </id_info>
  <brief_title>Deanxit and Rivotril in Tinnitus Patients</brief_title>
  <official_title>Additional Value of Deanxit in Tinnitus Patients Treated With Rivotril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether increased tinnitus reduction can be&#xD;
      obtained with Deanxit in patients already receiving Rivotril.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>3 weeks, 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Lactose placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1x/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deanxit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deanxit</intervention_name>
    <description>Deanxit 1x/day</description>
    <arm_group_label>Deanxit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose placebo</intervention_name>
    <description>Lactose used as placebo</description>
    <arm_group_label>Lactose placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pure tone, narrow band noise or polyphonic tinnitus&#xD;
&#xD;
          -  unilateral or bilateral tinnitus&#xD;
&#xD;
          -  VAS ≥ 4&#xD;
&#xD;
               -  cochleair origin tinnitus&#xD;
&#xD;
               -  tinnitus present 3 months or more&#xD;
&#xD;
               -  age 18y or more&#xD;
&#xD;
               -  intake Rivotril 1mg/d&#xD;
&#xD;
               -  patient 'able to cooperate'&#xD;
&#xD;
               -  patient able to fill in TQ en VAS&#xD;
&#xD;
               -  No pontine angle pathology on MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pulsatile tinnitus&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  contra-indications Deanxit&#xD;
&#xD;
          -  recovery myocard infarct&#xD;
&#xD;
          -  conduction disorder His&#xD;
&#xD;
          -  untreated glaucoma&#xD;
&#xD;
          -  MAO inhibitors: 15d stop&#xD;
&#xD;
          -  otosclerosis&#xD;
&#xD;
          -  middle ear pathologies&#xD;
&#xD;
          -  Ménière&#xD;
&#xD;
          -  somatic tinnitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Meeus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof Dr P H Van de Heyning</name_title>
    <organization>Antwerp University Hospital</organization>
  </responsible_party>
  <keyword>Tinnitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

